No Data
No Data
Trending Industry Today: Vertex Pharmaceuticals Leads Losses In Gene Editing Stocks
Beam Therapeutics Shares Fall After Q1 Net Loss Widens
Beam Therapeutics | 10-Q: Quarterly report
Express News | Beam Therapeutics Inc: Ended Q1 With $1.2 Bln in Cash, Cash Equivalents and Marketable Securities
Express News | Beam Therapeutics Inc: Cash Runway Expected to Support Operating Plans Into 2028
Beam Therapeutics | 8-K: Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights